A NOVEL BIS-INDOLE COMPOUND AGAINST CATHETER COLONIZATION

一种抗导管定植的新型双吲哚化合物

基本信息

  • 批准号:
    8318570
  • 负责人:
  • 金额:
    $ 30万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-08-15 至 2014-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Infections associated with medical devices can be serious and even fatal. Catheter colonization and production of a biofilm on the surface of a catheter shortly after implantation are normally the prelude for infections. A number of antimicrobial-treated catheters have been developed to combat these infections, however, many of them have limited clinical efficacy. Thus, the prevention of catheter-associated infections remains a major unmet medical need. To combat this problem, we have developed an innovative catheter coating that has been shown to be effective in preventing catheter colonization by Gram-positive and Gram-negative pathogens. The innovative catheter coating consists of MBX-1631, a novel broad-spectrum antimicrobial agent that was developed by Microbiotix, Inc. The overall goal of the proposed research is to develop antimicrobial coatings for medical devices that will prevent device-associated infections. In Phase I, we will formulate device coatings containing MBX-1631 and several analogs, and we will use them to coat medical device materials. The anti-biofilm properties and cytotoxicity of these coated devices will be tested in a series of in-vitro assays to evaluate their efficacy and selectivity. In addition, the several physical parameters of the coated devices, such as elution kinetics and durability, will be evaluated. Finally, selected coated devices will be evaluated in animal models to test for their antimicrobial efficacy and toxicity. Compounds that meet specified criteria for efficacy, selectivity, and physical properties will be developed further in Phase II. In Phase I we will accomplish the following specific aims: Aim 1. Formulate and apply catheter coatings consisting of MBX-1631 and several analogs; Aim 2. Evaluate the efficacy in preventing bacterial colonization, selectivity, and physical properties of coated materials using in-vitro assays; Aim 3. Evaluate efficacy and selectivity of coated materials in animal models of foreign body infection and acute toxicity.
描述(由申请人提供):与医疗器械相关的感染可能是严重的,甚至是致命的。导管定植和植入后不久导管表面产生生物膜通常是感染的前奏。已经开发了许多抗菌治疗的导管来对抗这些感染,然而,其中许多临床疗效有限。因此,预防导管相关性感染仍然是一个主要的未得到满足的医疗需求。为了解决这个问题,我们开发了一种创新的导管涂层,已经被证明在防止革兰氏阳性和革兰氏阴性病原体的导管定植方面是有效的。这种创新的导管涂层由MBX-1631组成,这是一种由MicroBiotix公司开发的新型广谱抗菌剂。拟议研究的总体目标是开发用于医疗设备的抗菌涂层,以防止设备相关感染。在第一阶段,我们将配制含有MBX-1631和几种类似物的设备涂层,并将它们用于医疗设备材料的涂层。这些涂层设备的抗生物被膜性能和细胞毒性将在一系列体外测试中进行测试,以评估其有效性和选择性。此外,还将评估涂层装置的几个物理参数,如洗脱动力学和耐久性。最后,选定的涂层设备将在动物模型中进行评估,以测试其抗菌效果和毒性。在第二阶段,我们将进一步开发符合特定疗效、选择性和物理性能标准的化合物。在第一阶段,我们将完成以下具体目标:目标1.研制和应用由MBX-1631和几种类似物组成的导管涂层;目标2.通过体外分析评估涂层材料在防止细菌定植、选择性和物理性能方面的有效性;目标3.在异物感染和急性毒性动物模型中评价涂层材料的有效性和选择性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TIMOTHY J OPPERMAN其他文献

TIMOTHY J OPPERMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('TIMOTHY J OPPERMAN', 18)}}的其他基金

Type 3 secretion system inhibitors to treat Pseudomonas aeruginosa keratitis
3型分泌系统抑制剂治疗铜绿假单胞菌角膜炎
  • 批准号:
    10484345
  • 财政年份:
    2022
  • 资助金额:
    $ 30万
  • 项目类别:
Inhibitors of wall teichoic acid biosynthesis of Staphylococcus aureus
金黄色葡萄球菌壁磷壁酸生物合成抑制剂
  • 批准号:
    8423694
  • 财政年份:
    2012
  • 资助金额:
    $ 30万
  • 项目类别:
Optimization of novel pyranopyridine efflux pump inhibitors
新型吡喃吡啶外排泵抑制剂的优化
  • 批准号:
    10227128
  • 财政年份:
    2012
  • 资助金额:
    $ 30万
  • 项目类别:
Inhibitors of wall teichoic acid biosynthesis of Staphylococcus aureus
金黄色葡萄球菌壁磷壁酸生物合成抑制剂
  • 批准号:
    8250668
  • 财政年份:
    2012
  • 资助金额:
    $ 30万
  • 项目类别:
Novel aryl-rhodanine inhibitors of Streptococcus mutans biofilms
变形链球菌生物膜的新型芳基绕丹宁抑制剂
  • 批准号:
    8393306
  • 财政年份:
    2012
  • 资助金额:
    $ 30万
  • 项目类别:
Optimization of novel pyranopyridine efflux pump inhibitors
新型吡喃吡啶外排泵抑制剂的优化
  • 批准号:
    9206472
  • 财政年份:
    2012
  • 资助金额:
    $ 30万
  • 项目类别:
Optimization of novel pyranopyridine efflux pump inhibitors
新型吡喃吡啶外排泵抑制剂的优化
  • 批准号:
    9011499
  • 财政年份:
    2012
  • 资助金额:
    $ 30万
  • 项目类别:
A NOVEL BIS-INDOLE COMPOUND AGAINST CATHETER COLONIZATION
一种抗导管定植的新型双吲哚化合物
  • 批准号:
    8200796
  • 财政年份:
    2011
  • 资助金额:
    $ 30万
  • 项目类别:
Antibiotic Potentiators Targeting SOS Induction
针对 SOS 诱导的抗生素增效剂
  • 批准号:
    7537576
  • 财政年份:
    2008
  • 资助金额:
    $ 30万
  • 项目类别:
Antibiotic Potentiators Targeting SOS Induction
针对 SOS 诱导的抗生素增效剂
  • 批准号:
    7658098
  • 财政年份:
    2008
  • 资助金额:
    $ 30万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 30万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 30万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 30万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 30万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了